Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 16, 2016 - Issue 10
Submit an article Journal homepage
401
Views
22
CrossRef citations to date
0
Altmetric
Review

Chronic migraine treatment: from OnabotulinumtoxinA onwards

Andrea NegroDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy;Regional Referral Headache Centre, Sant’Andrea Hospital, Rome, ItalyCorrespondence[email protected]
,
Martina CurtoDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy;Regional Referral Headache Centre, Sant’Andrea Hospital, Rome, Italy;Department of Psychiatry, Harvard Medical School, Boston, MA, USA;Bipolar & Psychotic Disorders Program, McLean Hospital, Belmont, Massachusetts, USA
,
Luana LionettoAdvanced Molecular Diagnostics, IDI-IRCCS, Rome, Italy
,
Maria Adele GiamberardinoHeadache Center and Geriatrics Clinic, Department of Medicine and Science of Aging, Gabriele D’Annunzio University, Chieti, Italy
&
Paolo MartellettiDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy;Regional Referral Headache Centre, Sant’Andrea Hospital, Rome, Italy
Pages 1217-1227 | Received 01 Apr 2016, Accepted 09 Jun 2016, Published online: 04 Jul 2016

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Shouyi Wu, Yajun Lian, Haifeng Zhang, Yuan Chen, Chuanjie Wu, Shuang Li, Yake Zheng, Yuhan Wang, Wenchao Cheng & Zhi Huang. (2019) Botulinum Toxin Type A for refractory trigeminal neuralgia in older patients: a better therapeutic effect. Journal of Pain Research 12, pages 2177-2186.
Read now
Andrea Negro & Paolo Martelletti. (2019) Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies. Expert Review of Neurotherapeutics 19:8, pages 769-776.
Read now
János Tajti, Délia Szok, Aliz Nyári & László Vécsei. (2019) Therapeutic strategies that act on the peripheral nervous system in primary headache disorders. Expert Review of Neurotherapeutics 19:6, pages 509-533.
Read now
Maria Adele Giamberardino, Giannapia Affaitati, Raffaele Costantini, Francesco Cipollone & Paolo Martelletti. (2017) Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab. Journal of Pain Research 10, pages 2751-2760.
Read now
Paolo Martelletti. (2017) Acute treatment of migraine: quo vadis?. Expert Opinion on Pharmacotherapy 18:11, pages 1035-1037.
Read now

Articles from other publishers (17)

S. Santos-Lasaosa, R. Belvís, M.L. Cuadrado, S. Díaz-Insa, A. Gago-Veiga, A.L. Guerrero-Peral, M. Huerta, P. Irimia, J.M. Láinez, G. Latorre, R. Leira, J. Pascual, J. Porta-Etessam, M. Sánchez del Río, J. Viguera & P. Pozo-Rosich. (2022) Calcitonin gene–related peptide in migraine: from pathophysiology to treatment. Neurología (English Edition) 37:5, pages 390-402.
Crossref
S. Santos-Lasaosa, R. Belvís, M.L. Cuadrado, S. Díaz-Insa, A. Gago-Veiga, A.L. Guerrero-Peral, M. Huerta, P. Irimia, J.M. Láinez, G. Latorre, R. Leira, J. Pascual, J. Porta-Etessam, M. Sánchez del Río, J. Viguera & P. Pozo-Rosich. (2022) CGRP en migraña: de la fisiopatología a la terapéutica. Neurología 37:5, pages 390-402.
Crossref
Ahmed Taher Masoud, Mohammed Tarek Hasan, Ahmed Sayed, Harvey Nabil Edward, Ahmed Mohamed Amer, Abdelrahman Elshahat Naga, Mohamed Elfil, Badrah S. Alghamdi, Asma Perveen, Ghulam Md Ashraf & Eshak I. Bahbah. (2021) Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials. Journal of the Neurological Sciences 427, pages 117505.
Crossref
L.R. Mingazova, O.R. Orlova, M.I. Soiher, V.G. Bychenko & N.V. Komissarova. (2021) The effectiveness of botulinum therapy of trigeminal neuralgia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 121:6, pages 40.
Crossref
D. García-Azorin, S. Santos-Lasaosa, A. B. Gago-Veiga, J. Viguera Romero & A. L. Guerrero-Peral. (2019) Real world preventative drug management of migraine among Spanish neurologists. The Journal of Headache and Pain 20:1.
Crossref
Theodoros Mavridis, Chrysa Koniari, Nikolaos Fakas & Dimos D. Mitsikostas. (2019) Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? A Literature Review. EMJ Innovations, pages 64-72.
Crossref
Michail Vikelis, Andreas A. Argyriou, Emmanouil V. Dermitzakis, Konstantinos C. Spingos, Nikolaos Makris & Evangelia Kararizou. (2018) Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment. The Journal of Headache and Pain 19:1.
Crossref
Paolo Martelletti. (2018) The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine. The Journal of Headache and Pain 19:1.
Crossref
Robert P. Cowan. (2018) The Future of Migraine Prevention. Headache: The Journal of Head and Face Pain 58, pages 291-297.
Crossref
Yuewei Wu-Fienberg, Hossein Ansari, Shawn Zardouz, Samer Narouze, Taryn Blaha, Marco Swanson & Ali Totonchi. (2018) Anatomical Look Into OnabotulinumtoxinA Injection for Chronic Migraine Headache. Regional Anesthesia and Pain Medicine 43:8, pages 869-874.
Crossref
Haifeng Zhang, Yajun Lian, Nanchang Xie, Chen Chen & Yake Zheng. (2017) Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study. The Journal of Headache and Pain 18:1.
Crossref
Min Hou, Haiyan Xing, Yongqing Cai, Bin Li, Xianfeng Wang, Pan Li, Xiaolin Hu & Jianhong Chen. (2017) The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. The Journal of Headache and Pain 18:1.
Crossref
Giorgio Sandrini, Roberto De Icco, Cristina Tassorelli, Nicola Smania & Stefano Tamburin. (2017) Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia. The Journal of Headache and Pain 18:1.
Crossref
Paolo Martelletti. (2017) The Application of CGRP(r) Monoclonal Antibodies in Migraine Spectrum: Needs and Priorities. BioDrugs 31:6, pages 483-485.
Crossref
Lanfranco Pellesi, Simona Guerzoni & Luigi Alberto Pini. (2017) Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. Clinical Pharmacology in Drug Development 6:6, pages 534-547.
Crossref
Andrea Negro, Martina Curto, Luana Lionetto, Simona Guerzoni, Luigi Alberto Pini & Paolo Martelletti. (2017) A Critical Evaluation on MOH Current Treatments. Current Treatment Options in Neurology 19:9.
Crossref
I. Aicua-Rapun, E. Martínez-Velasco, A. Rojo, A. Hernando, M. Ruiz, A. Carreres, E. Porqueres, S. Herrero, F. Iglesias & A. L. Guerrero. (2016) Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year. The Journal of Headache and Pain 17:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.